We represented Vividion Therapeutics’ founding chemist in knocking out claims alleging that he conspired to divert valuable intellectual property from the company’s $2 billion sale to Bayer. A Vividion investor sued for breach of fiduciary duty, fraud, aiding and abetting, and unjust enrichment after one of the scientist’s patents was licensed to a subsequent life sciences startup. The Delaware Chancery Court dismissed the case with prejudice after concluding that the claims were derivative, not direct, and that plaintiffs’ allegations were insufficient to take advantage of an exception to the ordinary rules for derivative claims.

We represented a nonprofit research institute in its lawsuit against a giant pharmaceutical company regarding the latter’s refusal to pay hundreds of millions of dollars in royalties it was owed for its intellectual property in a blockbuster drug. Following positive rulings on the merits of the case, we negotiated a very favorable settlement that entitles our client to ongoing royalties.

We defended The Scripps Research Institute and two award-winning chemists against a lawsuit brought by a venture capital firm partner who alleged he had entered into an oral joint venture agreement to develop and commercialize groundbreaking carbon-hydrogen activation technology. After nearly 18 months of litigation, the court granted summary judgment in favor of defendants, which was affirmed on appeal.

We currently represent Shareholder Representative Services (SRS) in its capacity as representative of the former shareholders of Ablation Frontiers Inc. in a post-merger dispute with Medtronic, Inc. in Delaware Chancery Court. Medtronic has refused to make milestone payments totaling $175 million that are due to the former shareholders based on recent FDA approvals of a novel catheter Ablation Frontiers invented and developed for treatment of atrial fibrillation prior to the merger

We are defending generative AI platform Runway in a copyright lawsuit filed by illustrators and visual artists alleging use of their works to train image models amounts to copyright infringement. We successfully narrowed the case through motion practice to eliminate claims under the Digital Millennium Copyright Act and the California state law claims.

We represented two former company executives in a securities fraud action arising out of a tender offer. We obtained a favorable settlement before depositions began.

We represented Calithera Biosciences, an early-stage drug development company, in a milestone dispute arising out of a collaboration agreement. We obtained a favorable settlement before depositions began.

We represented Nextiva, Inc., as defendant and counterclaimant in a trade libel, defamation, and false advertising suit. We succeeded in significantly narrowing the case against Nextiva on summary judgment and then favorably resolved the remainder of the litigation on the eve of trial.

We represented Angelo Rodriguez, a paraplegic former inmate, in a Federal Tort Claims Act suit regarding his treatment in prison. We settled on favorable terms shortly before discovery began.

We represented Major League Baseball, the Commissioner, and the 30 Clubs in a putative class action concerning the postponement of games during the COVID-19 pandemic. Plaintiffs raised a number of consumer claims and sought damages related to the sale of all tickets for the 2020 MLB season. The Court granted our motions to dismiss plaintiffs’ claims, holding them to be legally baseless.

We represented Shareholder Representative Services (SRS) in its role as representative of the former shareholders of FerroKin Biosciences in a post-merger dispute with Shire Pharmaceuticals, which had refused to make a $45 million milestone payment related to the development of an experimental iron chelation drug. After a four-day bench trial, the Delaware Chancery Court entered judgment in favor of SRS, ruling in a 77-page opinion that the former FerroKin shareholders were entitled to the overdue $45 million milestone, as well as five years of interest on the payment and their attorneys’ fees and costs, which totaled more than $80 million. The judgment of the Court of Chancery was unanimously affirmed by the Delaware Supreme Court.

We negotiated a settlement for Sutter Health with the California Attorney General’s Office, in a suit that alleged Sutter exploited its size and reach to extract “illegally inflated prices” from insurers, employers, and patients.

We represented Tour de France winner Lance Armstrong in settling a False Claims Act case brought by a former teammate and joined in by the United States. The Postal Service and Floyd Landis had sought $100 million in damages from Armstrong, but in light of several significant court rulings rejecting and limiting the plaintiffs’ damages theories, the case settled for $5 million. Our prior representation of Armstrong resulted in the closing of a federal criminal investigation without charges being filed.

In partnership with the ACLU, we filed a class action lawsuit challenging President Trump's executive order restricting immigration from several predominantly Muslim countries and suspending entry of refugees from all countries. The suit alleged that the order was an unconstitutional attempt to discriminate against Muslims, and that the government's actions violated Article I of the Constitution, the First Amendment, the equal-protection and due process rights granted under the Fifth Amendment and the Immigration and Nationality Act.